COLLAGEN CORP. ANNOUNCES FOURTH QUARTER AND YEAR-END RESULTS -- Company reports 86% increase in EPS and 38% increase in Operating Earnings for the year.PALO ALTO Palo Alto, city, California
Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , Calif.--(BUSINESS WIRE)--Aug. 16, 1995--Collagen Corporation today reported its fourth quarter and fiscal year-end Fiscal Year-End
The completion of a one-year, or 12-month, accounting period.
The reason that a company's fiscal year often differs from the calendar year and does not close on Dec 31, is due to the nature of company's needs. results which included revenues of $72.6 million, operating income Operating Income
The profit realized from a business' own operations.
This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit. of $11.9 million and net income of $8.8 million, or $0.93 per share, for the fiscal year ended June 30, 1995, compared with revenues of $65.6 million, operating income of $8.6 million and net income of $4.9 million, or $0.50 per share, in fiscal 1994. This represents an 11 percent increase in revenues, a 38 percent increase in operating income, and an 86 percent increase in earnings per share compared with fiscal 1994. Return on sales Return on sales
A measurement of operational efficiency equalingnet pre-tax profits divided by net sales expressed as a percentage.
return on sales
The portion of each dollar of sales that a firm is able to turn into income. increased from 8 percent in fiscal 1994 to 12 percent in fiscal 1995 and return on stockholders' equity Stockholders' Equity
The portion of the balance sheet that includes capital received from investors in exchange for stock (paid-in capital), donated capital, and retained earnings. This is equal to total assets minus liabilities, preferred stock and intangible assets. increased from 10 percent in fiscal 1994 to 18 percent in fiscal 1995.
Gross margin as a percentage of sales improved during fiscal 1995 to 74 percent from 71 percent during fiscal 1994. Selling, general and administrative ("SG&A") expenses increased to 45 percent of sales in fiscal 1995, from 44 percent in fiscal 1994, while research and development ("R&D") expenses as a percentage of sales declined to 14 percent from 15 percent in fiscal 1994.
For the fourth quarter ended June 30, 1995, Collagen collagen (kŏl`əjən), any of a group of proteins found in skin, ligaments, tendons, bone and cartilage, and other connective tissue. Cells called fibroblasts form the various fibers in connective tissue in the body. reported revenues of $20.2 million, operating income of $3.2 million and net income of $2.7 million, or $0.29 per share, compared with revenues of $18.7 million, operating income of $2.7 million and net income of $1.6 million, or $0.17 per share, during the prior year period. This represents an 8 percent increase in revenues, a 19 percent increase in operating income, and a 71 percent increase in earnings per share compared with the prior year period.
Worldwide revenues from the Company's dermatology dermatology (dûrmətŏl`əjē), branch of medicine concerned with diagnosis and treatment of diseases and disorders of the skin. and plastic surgery products increased 20 percent to $14.9 million during the fiscal 1995 fourth quarter, compared with $12.4 million in the prior year period. Revenues for the fourth quarter were positively impacted by approximately $500,000 of favorable fa·vor·a·ble
1. Advantageous; helpful: favorable winds.
2. Encouraging; propitious: a favorable diagnosis.
3. foreign exchange rate movements, compared with the prior year period. Unit sales unit sales
Sales measured in terms of physical units rather than dollars. Unit sales data are often used by financial analysts when evaluating the health of a company. increased approximately 22 percent on a worldwide basis compared with the prior year fourth quarter. Worldwide revenues from the sales of these products totaled $51.5 million for fiscal 1995, compared with $43.5 million in fiscal 1994, which represents an 18 percent increase in revenues for fiscal 1995.
"This past year we saw a gratifying grat·i·fy
tr.v. grat·i·fied, grat·i·fy·ing, grat·i·fies
1. To please or satisfy: His achievement gratified his father. See Synonyms at please.
2. revitalization re·vi·tal·ize
tr.v. re·vi·tal·ized, re·vi·tal·iz·ing, re·vi·tal·iz·es
To impart new life or vigor to: plans to revitalize inner-city neighborhoods; tried to revitalize a flagging economy. in the revenue growth of our dermatology and plastic surgery products business. For fiscal 1996, we expect to build on this success with the addition of sales people and the introduction of novel sales and marketing programs on a worldwide basis. We also plan to expand our offerings in this market franchise with the launch of the Trilucent(TM) breast implant breast implant, saline- or silicone-filled prosthesis used after mastectomy as a part of the breast reconstruction process or used cosmetically to augment small breasts. , which is manufactured by our affiliate, LipoMatrix, Incorporated, of Neuchatel, Switzerland. We are quite encouraged with the reception that the Trilucent(TM) implant implant /im·plant/ (im-plant´) to insert or to graft (tissue, or inert or radioactive material) into intact tissues or a body cavity. has received during the initial phases of its launch in the United Kingdom and we look forward to the roll-out of this product throughout the major markets of Europe over the next twelve months," stated Gary S. Petersmeyer, president and chief operating officer Chief Operating Officer (COO)
The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . "As part of our strategy to develop closer relationships with our physician customers, Collagen International recently formed a joint venture in Spain, Collagen Iberica, S.A., with our long-time distributor Quimigranel, S.A., to further our local presence in that country. We now have direct control of our sales efforts for our collagen implant products in 11 of our top 12 countries, including the U.S."
Contigen(R) Bard bard, in Wales, term originally used to refer to the order of minstrel-poets who composed and recited the poems that celebrated the feats of Celtic chieftains and warriors. collagen implant ("Contigen implant") revenues were $4.4 million for the fiscal 1995 fourth quarter, consisting of shipments to Collagen Corporation's marketing partner, C.R. Bard, Inc. ("Bard"), as well as income based on sales by Bard to physician customers in that quarter. This compares with $4.6 million in revenues during the same prior year period. Total Contigen implant revenues during fiscal 1995 were $16.5 million, compared with $16.7 million in fiscal 1994.
Combined fourth quarter revenues from sales of Collagraft(R) bone graft bone graft Orthopedic surgery Sterilized bony tissue, often of cadaveric origin, used to fill and/or 'sculpt' bone defects Indications Spinal fusion, revision of failed articular prostheses, filling traumatic or malignant bone defects, or periodontal defects. matrix ("Collagraft implant") and Collagraft(R) bone graft matrix strip ("Collagraft strip") were $820,000, compared with revenues of $1.1 million in the prior-year fourth quarter. Collagraft implant and Collagraft strip revenues totaled $3.0 million for fiscal 1995, compared with $2.7 million in fiscal 1994.
During fiscal 1995, Collagen Corporation sold an aggregate of 245,000 shares of Target Therapeutics therapeutics
Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , Inc. ("Target") common stock as part of its on-going program to generate cash for investments in current or new affiliates, corporate development programs, and other purposes. Collagen Corporation sold 75,000 shares of Target stock during the fiscal fourth quarter, contributing to a pre-tax gain on investments for the quarter of $2.0 million. As of June 30, 1995 Collagen Corporation owned approximately 2 million shares of Target stock, or about 29 percent of the outstanding shares of such company. Collagen's investment in Target has proven to be a very valuable asset and, over time, one that has increased in value despite the reduction in the Company's ownership position.
"We are delighted with the performance of our Target asset, and we expect to increase our activity in corporate and affiliate development by: expanding our presence in our cosmetic medical franchise; extending the uses of our collagen technology to other medical specialties Medical Specialties
See also anatomy; disease and illness; drugs; health; remedies; surgery.
the science of the description of glands. — adenographic, adj. and, enhancing our biomaterials technology," commented Howard D. Palefsky, chairman and chief executive officer.
Further increasing stockholder value, Collagen Corporation repurchased 300,000 shares of its common stock during the fiscal fourth quarter and a total of 562,500 shares during fiscal 1995. Collagen Corporation has repurchased a total of 1.5 million shares of its common stock, or 14 percent of outstanding shares, at an average acquisition price of approximately $22.00 per share, since the inception of the stock repurchase Stock repurchase
A firm's repurchase of outstanding shares of its common stock. program in February 1993. As of June 30, 1995, the Company had authorization to repurchase re·pur·chase
tr.v. re·pur·chased, re·pur·chas·ing, re·pur·chas·es
To buy (something) again.
The act of buying something that one previously sold or owned.
Noun 1. an additional 300,000 shares of its common stock in the open market.
Collagen Corporation is a technology-based company that develops, manufactures and markets biomedical bi·o·med·i·cal
1. Of or relating to biomedicine.
2. Of, relating to, or involving biological, medical, and physical sciences. devices for the treatment of defective defective adj. not being capable of fulfilling its function, ranging from a deed of land to a piece of equipment. (See: defect, defective title) , diseased dis·eased
1. Affected with disease.
2. Unsound or disordered. , traumatized or aging human tissues. -0-
COLLAGEN CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands)
June 30, 1995(a) 1994(a)
ASSETS Current assets: Cash, cash equivalents and short-term investments $ 9,384 $ 12,736 Accounts receivable, net 13,402 12,241 Inventories 5,056 3,861 Other current assets 5,568 3,305 Total current assets 33,410 32,143
Property and equipment, net 16,506 17,108 Intangible assets 2,727 2,243 Investments & other assets, principally Target Therapeutics, Inc. 24,263 23,011
$ 76,906 $ 74,505
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 2,250 $ 1,420 Accrued liabilities 10,862 10,245 Income taxes payable 5,902 4,251 Total current liabilities 19,014 15,916
Long-term liabilities Deferred income taxes 8,478 8,240 Other long-term liabilities 1,494 1,267 Total long-term liabilities 9,972 9,507
Stockholders' equity: Common stock 63,961 61,276 Retained earnings 16,669 9,234 Treasury stock (32,710) (21,428) Total stockholders' equity 47,920 49,082
$ 76,906 $ 74,505
(a) NOTE: Amounts derived from audited financial statements at dates indicated.
COLLAGEN CORPORATION CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (In thousands, except per share amounts)
Quarter Ended Years Ended June 30, June 30, 1995 1994 1995(a) 1994(a) Revenues: Product sales $20,226 $18,726 $71,560 $64,552 Other -- -- 1,000 1,000 20,226 18,726 72,560 65,552
Costs and expenses: Cost of sales 4,917 5,968 18,584 18,940 Research & development 2,672 2,377 9,943 9,366 Selling, general & administrative 9,405 7,666 32,179 28,639 16,994 16,011 60,706 56,945
Income from operations 3,232 2,715 11,854 8,607
Other income (expense): Gain on investments, net 1,766 -- 5,110 -- Equity in losses of affiliates, net (364) (115) (1,160) (269) Interest income 134 107 487 510 Interest expense (8) -- (91) --
Income before income taxes 4,760 2,707 16,200 8,848 Provision for income taxes 2,060 1,076 7,440 3,928
Net income $ 2,700 $ 1,631 $ 8,760 $ 4,920
Net income per share $ .29 $ .17 $ .93 $ .50
Shares used in calculating per share information 9,250 9,667 9,460 9,896
(a) NOTE: Amounts derived from audited financial statements for the periods indicated.
CONTACT: Collagen Corporation
David Foster This article or section resembles a .
Please help [ improve this article] by removing excessive trivia, irrelevant praise and criticism, lists and collections of links that are of . , 415/865-0200
Edelman Public Relations public relations, activities and policies used to create public interest in a person, idea, product, institution, or business establishment. By its nature, public relations is devoted to serving particular interests by presenting them to the public in the most
Jon Greer, 415/433-5381